Enhanced striatal dopamine D2 receptor-induced [35S]GTPγS binding after haloperidol treatment

European Journal of Pharmacology

Volumn 382, Issue 2, 1999, Pages 119-127

  Geurts, Muriel ^a   Hermans, Emmanuel ^a   Maloteaux, Jean Marie ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

35S GTP S, agonist induced; Catalepsy; Dopamine D2 receptor density; G protein coupling; Haloperidol

Indexed keywords

DOPAMINE 2 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR SENSITIVITY;

ANIMALS; APOMORPHINE; BINDING, COMPETITIVE; CATALEPSY; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HALOPERIDOL; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SPIPERONE; SULFUR RADIOISOTOPES; TRITIUM; UP-REGULATION;

EID: 0032879789     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00569-5     Document Type: Article

References (52)

1. Andersen P.H., Jansen J.A. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur. J. Pharmacol. Mol. Pharmacol. 188:1990;335-347.
2. 2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol. Toxicol. 62:1988;121-130.
3. i1 in rat central nervous tissues. J. Biochem. 108:1990;988-994.
4. Baker G.B., Greenshaw A.J. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell. Mol. Neurobiol. 9:1989;1-44.
5. Bernardi M.M., De Souza H., Palermo-Neto J. Effects of single and long-term haloperidol administration on open field behavior of rats. Psychopharmacology. 73:1981;171-175.
6. Boyson S.J., McGonigle P., Luthin G.R., Wolfe B.B., Molinoff P.B. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J. Pharmacol. Exp. Ther. 244:1988;987-993.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. 2. Mishra R.K., Baker G.B., Boulton A.A. Neuromethods, Vol. 31: G protein Methods and Protocols. 1997;119-138 Humana Press, Totowa, NJ.
9. Cox R.F., Waszczak B.L. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis. Brain Res. 534:1990;273-282.
10. Cubeddu L.X., Hoffmann I.S., James M.K., Niedzwiecki D.M. Changes in the sensitivity to apomorphine of dopamine receptors modulating dopamine and acetylcholine release after chronic treatment with bromocriptine or haloperidol. J. Pharmacol. Exp. Ther. 226:1983;680-685.
11. Dewey K.J., Fibiger H.C. The effects of dose and duration of chronic pimozide administration on dopamine receptor supersensitivity. Naunyn-Schmiedeberg's Arch. Pharmacol. 322:1983;261-270.
12. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum: Ach/dopamine/NMDA interactions. Trends Neurosci. 17:1994;228-233.
13. Dohlman H.G., Thorner J. RGS proteins and signaling by heterotrimeric G proteins. J. Biol. Chem. 272:1997;3871-3874.
14. Enz A., Goldstein M., Meller E. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum. Mol. Pharmacol. 37:1990;560-565.
15. 2(long) dopamine receptors: ligand binding and functional assays. Br. J. Pharmacol. 124:1998;978-984.
16. 35S]GTPγS binding. Life Sci. 65:1999;1633-1645.
17. Hacksell U., Jackson D.M., Mohell N. Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Pharmacol. Toxicol. 76:1995;320-324.
18. Hermans E., Challiss R.A.J., Nahorski S.R. Effects of varying the expression level of recombinant human mGlu1α receptors on the pharmacological properties of agonists and antagonists. Br. J. Pharmacol. 126:1999;873-882.
19. Hillegaart V., Ahlenius S., Magnusson O., Fowler C.J. Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Pharmacol. Biochem. Behav. 27:1987;159-164.
20. Iwata S., Izumi K., Shimizu T., Fukuda T. Effects of repeated testing on the incidence of haloperidol-induced catalepsy in mice. Pharmacol. Biochem. Behav. 33:1989;705-707.
21. Karolewicz B., Antkiewicz-Michaluk L., Michaluk J., Vetulani J. Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. Eur. J. Pharmacol. 313:1996;181-186.
22. Keen M. Testing models of agonism for G protein-coupled receptors. Trends Pharmacol. Sci. 12:1991;371-374.
23. Kenakin T. The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol. Rev. 48:1996;413-463.
24. Klawans H.L. Jr. The pharmacology of tardive dyskinesias. Am. J. Psychiatry. 130:1973;82-86.
25. LaHoste G.J., Marshall J.F. New concepts in dopamine receptor plasticity. Ann. N.Y. Acad. Sci. 702:1993;183-196.
26. 35S]GTPγS binding to cell membranes. Challiss R.A.J. Methods in Molecular Biology, Vol. 83, Receptor Signal Transduction Protocols. 1997;107-116 Humana Press, Totowa, NJ.
27. Li R., Wing L.L., Kirch D.G., Wyatt R.J., Chuang D.M. Effects of chronic nicotine and haloperidol administration on muscarinic receptor-mediated phosphoinositide turnover in rat brain slices. Psychopharmacology. 109:1992;248-250.
28. 2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. Eur. J. Pharmacol. 231:1993;191-196.
29. Meller E., Bohmaker K. Chronic treatment with antipsychotic drugs does not alter G protein alpha or beta subunit levels in rat brain. Neuropharmacology. 35:1996;1785-1791.
30. Meller E., Bohmaker K., Namba Y., Friedhoff A.J., Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol. Pharmacol. 31:1987;592-598.
31. Memo M., Pizzi M., Missale C., Carruba M.O., Spano P.F. Modification of the function of D1 and D2 dopamine receptors in striatum and nucleus accumbens of rats chronically treated with haloperidol. Neuropharmacology. 26:1987;477-480.
32. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotoninergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265:1993;207-217.
33. oα in discrete regions of rat brain. J. Neurochem. 55:1990;1079-1082.
34. 1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology. 36:1997;451-459.
35. 2 and muscarinic cholinergic receptors to their respective G proteins assessed by agonist-induced activation of high-affinity GTPase activity in rat striatal membranes. Biochem. Pharmacol. 50:1995;325-335.
36. Pedigo N.W. Jr. Neurotransmitter receptor plasticity in aging. Life Sci. 55:1994;1985-1991.
37. 2 dopamine receptors. Mol. Pharmacol. 48:1995;730-737.
38. 35S]GTPγS) binding in rat striatal membranes. Biochem. Pharmacol. 57:1999;155-162.
39. Sayers A.C., Burki H.R., Ruch W., Asper H. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia. 41:1975;97-104.
40. Schettini G., Ventra C., Florio T., Grimaldi M., Meucci O., Marino A. Modulation by GTP of basal and agonist-stimulated striatal adenylate cyclase activity following chronic blockade of D1 and D2 dopamine receptors: involvement of G proteins in the development of receptor supersensitivity. J. Neurochem. 59:1992;1667-1674.
41. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
42. Schröder U., Schröder H., Augustin W., Sabel B.A. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol binding. J. Pharmacol. Exp. Ther. 271:1994;1193-1196.
43. See R.E., Toga A.W., Ellison G. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. Neural Transm. Gen. Sect. 82:1990;93-109.
44. See R.E., Striplin C., Kalivas P.W. Chronic haloperidol does not alter G protein alpha-subunit levels in rats. Brain Res. Mol. Brain Res. 19:1993;219-221.
45. Shaul P.W., Anderson R.G. Role of plasmalemmal caveolae in signal transduction. Am. J. Physiol. 275:1998;L843-L851.
46. Sibley D.R., Neve K.A. Regulation of dopamine receptor function and expression. Neve K.A., Neve R.L. The Dopamine Receptors. 1997;383-424 Humana Press, Totowa, NJ.
47. 2-like receptors. Clin. Exp. Pharmacol. Physiol. 26:1999;S3-S9. suppl.
48. Tarsy D. Neuroleptic-induced movement disorders. Quinn N.P., Jenner P.G. Disorders of Movement. Clinical, Pharmacological and Physiological Aspects. 1989;361-393 Academic Press, London, GB.
49. i-proteins underlie adenylyl cyclase sensitization in morphine-treated rat striatal neurons. Eur. J. Pharmacol. Mol. Pharmacol. 245:1993;23-29.
50. Vogelsang G.D., Piercey M.F. The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol. Eur. J. Pharmacol. 110:1985;267-269.
51. 1 dopamine receptor agonists. Synapse. 21:1995;177-187.
52. Yamane H.K., Fung B.K.K. Covalent modifications of G-proteins. Annu. Rev. Pharmacol. Toxicol. 32:1993;201-241.